Yinghui Li

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 19

Top Topics

Multiple Myeloma

Transcription Factor

Top Venues

Communications biology

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Nicholas Sim, Jean-Michel Carter, Kamalakshi Deka, Benita Kiat Tee Tan, Yirong Sim, Suet-Mien Tan, Yinghui Li
TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer. Nature communications 15 (1) (2024)
Nicholas Sim, Jean-Michel Carter, Kamalakshi Deka, Benita Kiat Tee Tan, Yirong Sim, Suet-Mien Tan, Yinghui Li
TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer. Nature communications 15 (1) (2024)
Nicholas Sim, Jean-Michel Carter, Kamalakshi Deka, Benita Kiat Tee Tan, Yirong Sim, Suet-Mien Tan, Yinghui Li
TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer. Nature communications 15 (1) (2024)
Nicholas Sim, Jean-Michel Carter, Kamalakshi Deka, Benita Kiat Tee Tan, Yirong Sim, Suet-Mien Tan, Yinghui Li
TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer. Nature communications 15 (1) (2024)
Daniel Aron Ang, Jean-Michel Carter, Kamalakshi Deka, Joel H L Tan, Jianbiao Zhou, Qingfeng Chen, Wee Joo Chng, Nathan Harmston, Yinghui Li
Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma. Nature communications 15 (1) (2024)
Daniel Aron Ang, Jean-Michel Carter, Kamalakshi Deka, Joel H L Tan, Jianbiao Zhou, Qingfeng Chen, Wee Joo Chng, Nathan Harmston, Yinghui Li
Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma. Nature communications 15 (1) (2024)
Daniel Aron Ang, Jean-Michel Carter, Kamalakshi Deka, Joel H L Tan, Jianbiao Zhou, Qingfeng Chen, Wee Joo Chng, Nathan Harmston, Yinghui Li
Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma. Nature communications 15 (1) (2024)
Nicholas Sim, Yinghui Li
NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression. Communications biology 6 (1) (2023)
Nicholas Sim, Yinghui Li
NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression. Communications biology 6 (1) (2023)
Nicholas Sim, Yinghui Li
NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression. Communications biology 6 (1) (2023)
Kamalakshi Deka, Yinghui Li
Transcriptional Regulation during Aberrant Activation of NF-κB Signalling in Cancer. Cells 12 (5) (2023)
Nicholas Sim, Yinghui Li
NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression. Communications biology 6 (1) (2023)
Kamalakshi Deka, Yinghui Li
Transcriptional Regulation during Aberrant Activation of NF-κB Signalling in Cancer. Cells 12 (5) (2023)
Nicholas Sim, Yinghui Li
NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression. Communications biology 6 (1) (2023)
Kamalakshi Deka, Yinghui Li
Transcriptional Regulation during Aberrant Activation of NF-κB Signalling in Cancer. Cells 12 (5) (2023)
Nicholas Sim, Yinghui Li
NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression. Communications biology 6 (1) (2023)
Nicholas Sim, Yinghui Li
NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression. Communications biology 6 (1) (2023)
Nicholas Sim, Yinghui Li
NF-κB/p52 augments ETS1 binding genome-wide to promote glioma progression. Communications biology 6 (1) (2023)
Shen Kiat Lim, Chen Chen Peng, Shannon Low, Varsheni Vijay, Andrea Budiman, Beng Hooi Phang, Jing-Quan Lim, Anand D Jeyasekharan, Soon Thye Lim, Choon-Kiat Ong, Suet-Mien Tan, Yinghui Li
Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL. Leukemia (2022)